Barclays Maintains Overweight on Bruker, Lowers Price Target to $45

Benzinga Newsdesk www.benzinga.com Negative 83.8%

Neg 83.8% Neu 0% Pos 0%

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and lowers the price target from $50 to $45.